No Data
US Manufacturing Index Rises To 43, Highest Since 2020
Piper Sandler Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $160
Neurocrine Biosciences To Present At UBS Global Healthcare Conference; Webcast At 4:15 PM ET
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
AbbVie's Disappointing Schizophrenia Drug Trial Bodes Well for Rival Bristol Myers, Analysts Say
Oppenheimer Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $192